Loading
Life sciences · Journal article
International Journal of Health Sciences · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Breast cancer (BC) is classified into luminal A, luminal B, Human epidermal growth factor 2 receptors positive, and triple-negative subtypes, with adjuvant endocrine therapy recommended for hormone receptor-positive disease. This study aimed to evaluate whether vitamin D and bone-modifying therapy improve quality of life in patients with non-metastatic luminal breast cancer receiving non-steroidal Aromatase Inhibitors (NSAI) and whether these improvements are associated with better overall and disease-free survival. Methods: This prospective study was executed on 100 female participants identified with postmenopausal non metastatic (M0) luminal BC, were randomly placed into two equal groups: Group A: treated with adjuvant NSAI plus vitamin D supplementation with bone antiresorptive agents and group B: treated with adjuvant NSAI plus vitamin D supplementation without bone antiresorptive agents. Results: The mean physical well-being scores were 23.86, 25.17, and 25.8 in group A and 21.7, 22.6, and 22.91 in group B, as listed, with a significant p-value. The mean functional well-being (FWB) scores were 23.66, 25.25, and 25.98 in group A relative to 21.44, 22.93, and 23.23 in group B (P<0.05). Conclusions: Vitamin D normalization and bone-modifying agents help preserve bone health and prevent bone loss in postmenopausal women with luminal BC receiving adjuvant NSAIs.